journal article·2018-10-31Open access

miR-124 inhibits progression of hepatocarcinoma by targeting KLF4 and promises a novel diagnostic marker

Li-Pei Wu, Jian Wu, Anquan Shang, Man Yang, Ling-Ling Li, Jing Yu, Lei-Rong Xu, Chun-Bing Wang, Wei-Wei Wang, Jian-Jun Zhu, Wen-Ying Lu

Abstract

Hepatocarcinoma is one of the most lethal malignancy haunting the Chinese population, which is partially due to the difficulties in diagnosis at an early stage. The search for a biomarker that could signify the presence and progress of hepatocarcinoma is never ended. MicroRNAs are 22-nt RNAs that could bind to 3' UTR of target mRNAs, mediating degradation of mRNAs or inhibiting the translation. Although much has been investigated, the role of miR-124 in hepatocarcinoma remained elusive. We first detected aberrant expression level of miR-124 in HCC tissues of 112 patients. By exploring the clinical parameters, we found a significantly inverse correlation between miR-124 level and TNM stages. Consistent with this, the survival analysis indicated the association of low miR-124 with longer survival time. Subsequent forced expression miR-124 resulted in reduced cell viability of Hep3B and SMMC-7221, which cell lines have high and low background expression of miR-124, respectively. TargetScan prediction rendered a subset of target candidates, which were selected for experimental validation, KLF4 was subject to luciferase assay. Ectopic expression of KLF4 increased the sphere formation ability and CD44/133-positive cell numbers, which can be reversed by abundant expression of miR-124, suggesting that KLF4 is a functional target of miR-124 in tumourigenesis and cancer progression of HCC.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: MicroRNA in disease regulation · Circular RNAs in diseases · Kruppel-like factors research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Clinical Laboratory, The Affiliated Dongtai Hospital of Nantong University

Department of Oncology, The Sixth People’s Hospital of Yancheng City

Department of Laboratory Medicine, Tongji Hospital of Tongji University

Department of Laboratory Medicine, The Sixth People’s Hospital of Yancheng City

Department of Laboratory Medicine, Yancheng TCM Hospital Affiliated to Nanjing University of Chinese Medicine

Department of Oncology, Yancheng Hospital Affiliated to Medical College of Southeast University and The Third People's Hospital of Yancheng City

Department of Pathology, The First People's Hospital of Yancheng City

Department of Pathology, The Sixth People’s Hospital of Yancheng City

Funding

The Three-year Planning for Strengthening the Construction of Public Health System

References (47)

Show source-provided references
1. 10.3322/canjclin.49.1.3310.3322/canjclin.49.1.33 ↗
2. 10.1371/journal.pmed.100162410.1371/journal.pmed.1001624 ↗
3. 10.1053/j.gastro.2011.12.06110.1053/j.gastro.2011.12.061 ↗
4. 10.1053/j.gastro.2007.04.06110.1053/j.gastro.2007.04.061 ↗
5. 10.1053/j.gastro.2015.12.04110.1053/j.gastro.2015.12.041 ↗
6. 10.3322/caac.2014110.3322/caac.20141 ↗
7. 10.1016/S0092-8674(04)00045-510.1016/S0092-8674(04)00045-5 ↗
8. 10.1126/science.111144410.1126/science.1111444 ↗
9. 10.1002/ijc.2239410.1002/ijc.22394 ↗
10. 10.1053/j.gastro.2007.05.02210.1053/j.gastro.2007.05.022 ↗
11. 10.1158/0008-5472.CAN-04-063710.1158/0008-5472.CAN-04-0637 ↗
12. Michael MZ, O’Connor SM, van Holst Pellekaan NG, et al. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res. 2003;1:882–891.
13. 10.3109/21691401.2015.108016810.3109/21691401.2015.1080168 ↗
14. 10.1080/21691401.2016.121685610.1080/21691401.2016.1216856 ↗
15. 10.3109/21691401.2015.108017110.3109/21691401.2015.1080171 ↗
16. 10.1080/21691401.2017.138974810.1080/21691401.2017.1389748 ↗
17. 10.1158/0008-5472.CAN-06-460710.1158/0008-5472.CAN-06-4607 ↗
18. 10.1053/j.gastro.2008.04.00310.1053/j.gastro.2008.04.003 ↗
19. 10.1002/hep.2215810.1002/hep.22158 ↗
20. 10.1111/j.1872-034X.2009.00502.x10.1111/j.1872-034X.2009.00502.x ↗
21. 10.1186/1471-2407-13-46910.1186/1471-2407-13-469 ↗
22. 10.1158/1078-0432.CCR-09-184010.1158/1078-0432.CCR-09-1840 ↗
23. 10.1111/jcmm.1276010.1111/jcmm.12760 ↗
24. 10.1007/s13277-015-4462-310.1007/s13277-015-4462-3 ↗
25. 10.1155/2013/92420610.1155/2013/924206 ↗
26. 10.1093/nar/gks78910.1093/nar/gks789 ↗
27. 10.1093/carcin/bgp25010.1093/carcin/bgp250 ↗
28. 10.1146/annurev.med.59.053006.10470710.1146/annurev.med.59.053006.104707 ↗
29. 10.1371/journal.pone.004713710.1371/journal.pone.0047137 ↗
30. 10.21037/hbsn.2016.05.0710.21037/hbsn.2016.05.07 ↗
31. 10.1186/1471-2164-14-39510.1186/1471-2164-14-395 ↗
32. 10.3748/wjg.v22.i4.148710.3748/wjg.v22.i4.1487 ↗
33. 10.7754/Clin.Lab.2015.15040810.7754/Clin.Lab.2015.150408 ↗
34. 10.1038/onc.2009.21110.1038/onc.2009.211 ↗
35. 10.3892/ol.2015.375910.3892/ol.2015.3759 ↗
36. 10.7554/eLife.0500510.7554/eLife.05005 ↗
37. 10.1002/cncr.2669810.1002/cncr.26698 ↗
38. 10.1016/S0006-291X(03)01356-110.1016/S0006-291X(03)01356-1 ↗
39. 10.1074/jbc.M20481620010.1074/jbc.M204816200 ↗
40. 10.1593/neo.9112210.1593/neo.91122 ↗
41. 10.1016/j.ajpath.2010.11.02110.1016/j.ajpath.2010.11.021 ↗
42. 10.1158/0008-5472.CAN-12-385910.1158/0008-5472.CAN-12-3859 ↗
43. 10.1016/j.bbamcr.2012.06.02710.1016/j.bbamcr.2012.06.027 ↗
44. 10.1128/MCB.00063-0910.1128/MCB.00063-09 ↗
45. 10.1158/0008-5472.CAN-04-361910.1158/0008-5472.CAN-04-3619 ↗
46. 10.1128/MCB.06306-1110.1128/MCB.06306-11 ↗
47. 10.3892/ol.2013.115110.3892/ol.2013.1151 ↗